Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is
becoming an emerging option for the treatment of cancers. Numerous LSD1 inhibitors have …

Considerable progress has been made in the development of anticancer agents over the
past few decades, and a lot of new anticancer agents from natural and synthetic sources …

Histone lysine-specific demethylase 1 (LSD1/KDM1A) was first identified in 2004 as an
epigenetic enzyme able to demethylate specific lysine residues of histone H3, namely …

In recent decades, the development of targeted drugs has featured prominently in the
treatment of cancer, which is among the major causes of mortality globally. Triazole-fused …

Natural products generally fall into the biologically relevant chemical space and always
possess novel biological activities, thus making them a rich source of lead compounds for …

As a flavin adenine dinucleotide (FAD)-dependent monoamine oxidase, lysine specific
demethylase 1 (LSD1/KDM1A) functions as a transcription coactivator or corepressor to …

Enantioselective difunctionalization of alkenes offers a straightforward means for the rapid
construction of enantioenriched complex molecules. Despite the tremendous efforts devoted …

Abstract Lysine-specific demethylase 1 (LSD1) is a FAD-dependent enzyme, which has
been proposed as a promising target for therapeutic cancer. Herein, a series of benzofuran …

Pragmatic insertion of pargyline, a LSD1 inhibitor, as a surface recognition part in the HDAC
inhibitory pharmacophore was planned in pursuit of furnishing potent antiprostate cancer …

An approach for the efficient synthesis of halogenated hydrazines via acid-mediated
electrophilic hydrazinative halogenation of alkenes is disclosed. This transformation …